title: Pharmacogenetic Risk Scores for Perindopril Clinical and Cost Effectiveness in Stable Coronary Artery Disease: When Are We Ready to Implement?
authors.affiliation: Ohio State University, College of Medicine, Center for Pharmacogenomics, Columbus, OH.
authors.forename: Jasmine A
authors.initials: JA
authors.lastname: Luzum
authors.affiliation: Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI Center for Health Policy and Health Services Research, Henry Ford Hospital, Detroit, MI dlanfea1@hfhs.org.
authors.forename: David E
authors.initials: DE
authors.lastname: Lanfear
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D003324:Coronary Artery Disease / Q000188:drug therapy*; D003362:Cost-Benefit Analysis; D006801:Humans; D020913:Perindopril; D010597:Pharmacogenetics
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D020913:Perindopril
keywords: Editorials; angiotensin‐converting enzyme inhibitor; cardiovascular disease; pharmacogenetics